Strategic nonmyeloablative conditioning: CD154:CD40 costimulatory blockade at primary bone marrow transplantation promotes engraftment for secondary bone marrow transplantation after engraftment failure

Journal of Immunology

Volumn 181, Issue 9, 2008, Pages 6616-6624

  Xu, Hong ^a   Huang, Yiming ^a   Chilton, Paula M ^a   Hussain, Lala Rukh ^a   Tanner, Michael K ^a   Yan, Jun ^b   Ildstad, Suzanne T ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA T CELL RECEPTOR ANTIBODY; ANTIBODY; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; GRAFT FAILURE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTOXICITY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; SENSITIZATION; T CELL DEPLETION; T LYMPHOCYTE; TREATMENT FAILURE; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BAGG ALBINO MOUSE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CHRONIC DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; REOPERATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD40; BONE MARROW TRANSPLANTATION; CD40 LIGAND; CHRONIC DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; REOPERATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 58749099805     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.9.6616     Document Type: Article

References (51)

1. Ildstad, S. T., and W. C. Breidenbach. 2007. Tolerance to organ transplants: is chimerism bringing it closer than we think? Curr. Opin. Organ Transplant. 12: 329-334.
2. Li, H., C. L. Kaufman, S. S. Boggs, P. C. Johnson, K. D. Patrene, and S. T. Ildstad. 1996. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in non-obese diabetic (NOD) mice. J. Immunol. 156: 380-388. (Pubitemid 3024791)
3. Ildstad, S. T., and D. H. Sachs. 1984. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 307: 168-170.
4. Slavin, S., A. Nagler, E. Naparstek, Y. Kapelushnik, M. Aker, G. Cividalli, G. Varadi, M. Kirschbaum, A. Ackerstein, S. Samuel, et al. 1998. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91: 756-763. (Pubitemid 28078275)
5. Slavin, S., A. Nagler, M. Y. Shapira, M. Aker, C. Gabriel, and R. Or. 2002. Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation. J. Clin. Immunol. 22: 64-69.
6. Tsirigotis, P., R. O. Bitan, I. B. Resnick, S. Samuel, A. Ackerstein, S. Eladi, B. Gesundheit, I. Zilberman, S. Miron, A. Leubovic, et al. 2006. A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients. Haematologica 91: 852-855. (Pubitemid 44014560)
7. LeBlanc, K., M. Remberger, M. Uzunel, J. Mattsson, L. Barkholt, and O. Ringden. 2004. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation 78: 1014-1020. (Pubitemid 39391863)
8. Niederwieser, D., M. Maris, J. A. Shizuru, E. Petersdorf, U. Hegenbart, B. M., Sandmaier, D. G. Maloney, B. Storer, T. Lange, T. Chauncey, et al. 2003. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101: 1620-1629. (Pubitemid 36182543)
9. Gorin, N. C., M. Labopin, J. M. Boiron, N. Theorin, T. Littlewood, S. Slavin, H. Greinix, J. Y. Cahn, E. P. Alessandrino, A. Rambaldi, et al. 2006. Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond: the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. J. Clin. Oncol. 24: 3959-3966.
10. Jochum, C., M. Beste, E. Zellmer, S. S. Graves, and R. Storb. 2007. CD154 blockade and donor-specific transfusions in DLA-identical marrow transplantation in dogs conditioned with 1-Gy total body irradiation. Biol. Blood Marrow Transplant. 13: 164-171. (Pubitemid 46112376)
11. Warnecke, G., M. Avsar, M. Morancho, C. Peters, S. Thissen, B. Kruse, R. Baumann, H. Ungefroren, A. R. Simon, J. M. Hohlfeld, et al. 2006. Preoperative low-dose irradiation promotes long-term allograft acceptance and induces regulatory T cells in a porcine model of pulmonary transplantation. Transplantation 82: 93-101. (Pubitemid 44296983)
12. Colson, Y. L., S. M. Wren, M. J. Schuchert, K. D. Patrene, P. C. Johnson, S. S. Boggs, and S. T. Ildstad. 1995. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J. Immunol. 155: 4179-4188.
13. Xu, H., P. M. Chilton, Y. Huang, C. L. Schanie, and S. T. Ildstad. 2004. Production of donor T cells is critical for induction of donor-specific tolerance and maintenance of chimerism. J. Immunol. 172: 1463-1471. (Pubitemid 38116789)
14. Xu, H., P. M. Chilton, Y. Huang, C. L. Schanie, J. Yan, and S. T. Ildstad. 2007. Addition of cyclophosphamide to T-cell depletion based nonmyeloablative conditioning allows donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation. Transplantation 83: 954-963. (Pubitemid 46682738)
15. Taylor, P. A., C. J. Lees, J. M. Wilson, M. J. Ehrhardt, M. T. Campbell, R. J. Noelle, and B. R. Blazar. 2002. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood 100: 3400-3407.
16. Luo, B., S. A. Nanji, C. D. Schur, R. L. Pawlick, C. C. Anderson, and A. M. Shapiro. 2005. Robust tolerance to fully allogeneic islet transplants achieved by chimerism with minimal conditioning. Transplantation 80: 370-377. (Pubitemid 41129966)
17. Wekerle, T., J. Kurtz, H. Ito, J. V. Ronquillo, V. Dong, G. Zhao, J. Shaffer, M. H. Sayegh, and M. Sykes. 2000. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat. Med. 6: 464-469. (Pubitemid 30208167)
18. Domenig, C., A. Sanchez-Fueyo, J. Kurtz, S. P. Alexopoulos, C. Mariat, M. Sykes, T. B. Strom, and X. X. Zheng. 2005. Roles of deletion and regulation in creating mixed chimerism and allograft tolerance using a nonlymphoablative irradiation-free protocol. J. Immunol. 175: 51-60. (Pubitemid 40884301)
19. Sandmaier, B. M., S. Mackinnon, and R. W. Childs. 2007. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol. Blood Marrow Transplant. 13: 87-97. (Pubitemid 46044111)
20. Girgis, M., C. Hallemeier, W. Blum, R. Brown, H. S. Lin, H. Khoury, L. T. Goodnough, R. Vij, S. Devine, M. Wehde, S. Postma, et al. 2005. Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide. Blood 105: 3035-3041. (Pubitemid 40504318)
21. Xu, H., J. Yan, Y. Huang, P. M. Chilton, C. Ding, C. L. Schanie, L. Wang, and S. T. Ildstad. 2008. Co-stimulatory blockade of CD154:CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization. Blood 111: 3266-3275.
22. Parameswaran, N., R. Suresh, V. Bal, S. Rath, and A. George. 2005. Lack of ICAM-1 on APCs during T cell priming leads to poor generation of central memory cells. J. Immunol. 175: 2201-2211. (Pubitemid 41113826)
23. Ichii, H., A. Sakamoto, Y. Kuroda, and T. Tokuhisa. 2004. Bcl6 acts as an amplifier for the generation and proliferative capacity of central memory CD8+ T cells. J. Immunol. 173: 883-891. (Pubitemid 38924261)
24. + T cells by skin grafts via direct antigen presentation. J. Immunol. 169: 1270-1276.
25. Neujahr, D. C., C. Chen, X. Huang, J. F. Markmann, S. Cobbold, H. Waldmann, M. H. Sayegh, W. W. Hancock, and L. A. Turka. 2006. Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J. Immunol. 176: 4632-4639.
26. Cho, B. K., V. P. Rao, Q. Ge, H. N. Eisen, and J. Chen. 2000. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J. Exp. Med. 192: 549-556.
27. Lucarelli, G., M. Galimberti, P. Polchi, E. Angelucci, D. Baronciani, C. Giardini, P. Politi, S. M. T. Durazzi, P. Muretto, and F. Albertini. 1990. Bone marrow transplantation in patients with thalassemia. N. Engl. J. Med. 322: 417-421. (Pubitemid 20059509)
28. Kodish, E., J. Lantos, C. Stocking, P. A. Singer, M. Siegler, and F. L. Johnson. 1991. Bone marrow transplantation for sickle cell disease. N. Engl. J. Med. 325: 1349-1353.
29. Ikehara, S., H. Ohtsuki, R. A. Good, H. Asamoto, T. Nakamura, K. Sekita, E. Muso, Y. Tochino, T. Ida, H. Kuzuya, et al. 1985. Prevention of type I diabetes in nonobese diabetic mice by allogeneic bone marrow transplantation. Proc. Natl. Acad. Sci. USA 82: 7743-7747. (Pubitemid 16204425)
30. Nelson, J. L., R. Torrez, F. M. Louie, O. S. Choe, R. Storb, and K. M. Sullivan. 1997. Pre-existing autoimmune disease in patients with longterm survival after allogeneic bone marrow transplantation. J. Rheumatol. 24: 23-29. (Pubitemid 27223595)
31. + cells in the recipient hematopoietic environment mediate resistance to engraftment of allogeneic donor bone marrow. J. Immunol. 168: 1636-1643.
32. Mapara, M. Y., M. Pelot, G. Zhao, K. Swenson, D. Pearson, and M. Sykes. 2001. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Biol. Blood Marrow Transplant. 7: 646-655.
33. + cells permits engraftment of bone marrow stem cells and tolerance induction with minimal conditioning. Surgery 122: 221-227.
34. + T cells play a nonredundant role in the rejection of heart allografts in mice. Surgery 126: 121-126.
35. Markees, T. G., N. E. Phillips, R. J. Noelle, L. D. Shultz, J. P. Mordes, D. L. Greiner, and A. A. Rossini. 1997. Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand. Transplantation 64: 329-335.
36. Noelle, R. J., M. Roy, D. M. Shepherd, I. Stamenkovic, J. A. Ledbetter, and A. Aruffo. 1992. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl. Acad. Sci. USA 89: 6550-6554.
37. Rossini, A. A., D. C. Parker, N. E. Phillips, F. H. Durie, R. J. Noelle, J. P. Mordes, and D. L. Greiner. 1996. Induction of immunological tolerance to islet allografts. Cell Transplant. 5: 49-52. (Pubitemid 26076602)
38. Roy, M., T. Waldschmidt, A. Aruffo, J. A. Ledbetter, and R. J. Noelle. 1993. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J. Immunol. 151: 2497-2510. (Pubitemid 23264502)
39. Clarkson, M. R., and M. H. Sayegh. 2005. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation 80: 555-563. (Pubitemid 41377737)
40. Van, K. C., and J. Banchereau. 1997. Functions of CD40 on B cells, dendritic cells and other cells. Curr. Opin. Immunol. 9: 330-337. (Pubitemid 27303501)
41. Rossini, A. A., D. L. Greiner, and J. P. Mordes. 1999. Induction of immunologic tolerance for transplantation. Physiol. Rev. 79: 99-141.
42. Monk, N. J., R. E. Hargreaves, J. E. Marsh, C. A. Farrar, S. H. Sacks, M. Millrain, E. Simpson, J. Dyson, and S. Jurcevic. 2003. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat. Med. 9: 1275-1280.
43. Van den Eertwegh, A. J., R. J. Neolle, M. Roy, D. M. Shepherd, A. Aruffo, J. A. Ledbetter, W. J. Boersma, and E. Claassen. 1993. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J. Exp. Med. 178: 1555-1565. (Pubitemid 23318434)
44. Whitmire, J. K., M. K. Slifka, I. S. Grewal, R. A. Flavell, and R. Ahmed. 1996. CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection. J. Virol. 70: 8375-8381.
45. Foy, T. M., J. D. Laman, J. A. Ledbetter, A. Aruffo, E. Claassen, and R. J. Noelle. 1994. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J. Exp. Med. 180: 157-163. (Pubitemid 24181064)
46. Grewal, I. S., and R. A. Flavell. 1998. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16: 111-135.
47. Morimoto, S., Y. Kanno, Y. Tanaka, Y. Tokano, H. Hashimoto, S. Jacquot, C. Morimoto, S. F. Schlossman, H. Yagita, K. Okumura, and T. Kobata. 2000. CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses. J. Immunol. 164: 4097-4104. (Pubitemid 30215065)
48. Wu, Z., S. J. Bensinger, J. Zhang, C. Chen, X. Yuan, X. Huang, J. F. Markmann, A. Kassaee, B. R. Rosengard, W. W. Hancock, et al. 2004. Homeostatic proliferation is a barrier to transplantation tolerance. Nat. Med. 10: 87-92. (Pubitemid 38524703)
49. Braun, W. E. 1989. Laboratory and clinical management of the highly sensitized organ transplant recipient. Hum. Immunol. 26: 245-260. (Pubitemid 20001194)
50. Xu, H., P. M. Chilton, M. K. Tanner, Y. Huang, C. L. Schanie, M. Dy-Liacco, J. Yan, and S. T. Ildstad. 2006. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood 108: 3611-3619. (Pubitemid 44776905)
51. Taylor, P. A., M. J. Ehrhardt, M. M. Roforth, J. M. Swedin, A. Panoskaltsis-Mortari, J. S. Serody, and B. R. Blazar. 2007. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 109: 1307-1315.